Liquid biopsy guided treatment for localized pancreatic cancer
Liquid Biopsy Guided Treatment in Localized Pancreatic Cancer (LIQUIPANC): Circulating Tumor DNA (ctDNA) as Precision Medicine Tool for Stratification of Neoadjuvant Chemotherapy vs. Upfront Surgery
This study is testing if using a blood test to guide treatment can help people with localized pancreatic cancer do better with chemotherapy instead of immediate surgery.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Elisabethinen Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Linz, Upper Austria) |
| Trial ID | NCT06391892 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of using liquid biopsy to guide treatment decisions in patients with localized pancreatic cancer, comparing neoadjuvant chemotherapy to standard upfront surgery. The approach focuses on patients with detectable circulating tumor DNA (ctDNA), who will receive chemotherapy instead of immediate surgery due to their higher risk of early recurrence. The study aims to determine the impact of this strategy on disease-free survival (DFS) and overall survival (OS) compared to traditional methods. By utilizing blood tests for ctDNA analysis, the study seeks to improve treatment outcomes and reduce unnecessary chemotherapy exposure.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with localized pancreatic cancer who are recommended for upfront surgery.
Not a fit: Patients with synchronous secondary malignancies or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve survival rates for patients with localized pancreatic cancer by allowing for more personalized treatment plans.
How similar studies have performed: Previous studies have shown promising results using ctDNA as a prognostic marker in cancer treatment, indicating potential success for this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Informed consent * \>18 years old * localized pancreatic cancer to go for upfront surgery Exclusion Criteria: * synchronous secondary malignancy * pregnancy
Where this trial is running
Linz, Upper Austria
- Ordensklinikum Linz Barmherzige Schwestern — Linz, Upper Austria, Austria (Recruiting)
Study contacts
- Principal investigator: Patrick Kirchweger, MD, PhD — Ordensklinikum Linz, Department of Surgery
- Study coordinator: Patrick Kirchweger, MD, PhD
- Email: patrick.kirchweger@ordensklinikum.at
- Phone: +436644159646
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.